UTAH MEDICAL PRODUCTS INC (UTMD) Form 10-Q — Aug 12, 2026
Utah Medical Products' second-quarter 2026 sales fell 14.3% year over year to $8.5 million, with net income down 11.9% to $2.7 million and diluted EPS of $0.844 versus $0.939 a year ago. First-half 2026 revenue declined 12.3% to $17.3 million. The decline stems mainly from the loss of UTMD's two previously largest customers — OEM partner PendoTECH and its former China distributor — which contributed zero sales in 2Q 2026 versus a combined $1,066 thousand a year earlier, while replacement biopharma OEM sales reached only $211 thousand in the first half, a slower ramp than planned.
Key figures
- Eps
- $0.844 diluted (2Q 2026); $1.661 diluted (1H 2026)
- Revenue
- 2Q 2026: $8,529 thousand; 1H 2026: $17,252 thousand
- Guidance
- 2026 consolidated sales projected to decline 10-13% vs 2025 (prior plan was roughly flat)
- Net Income
- $2,686 thousand (2Q 2026); $5,290 thousand (1H 2026)
- Total Debt
- $0 (no debt; total liabilities $2,539 thousand)
- Revenue Yoy
- -14.3% (2Q 2026); -12.3% (1H 2026)
- Total Assets
- $124,572 thousand
- Cash Position
- $87,528 thousand cash & investments at June 30, 2026
- Shares Outstanding
- 3183818
- Ttm Adjusted EBITDA
- $15,704 thousand
- Annualized ROE1 H2026
- 9%
- Dividends Paid1 H2026
- $1,976 thousand ($0.310/share)
- Adjusted EBITDA1 H2026
- $7,568 thousand (43.9% of sales)
- Adjusted EBITDA2 Q2026
- $3,587 thousand (42.1% of sales)
- Filshie Tariffs1 H2026
- $156 thousand, reduced gross margin 0.9 pts
- Litigation Fees2 Q2026
- $498 thousand
- Litigation Expense2025
- $1,355 thousand
- Effective Tax Rate2 Q2026
- 18.3% vs 20.5% in 2Q 2025
- Share Repurchases1 H2026
- 3,403 shares at $60.54 average ($206 thousand)
- Gross Profit Margin2 Q2026
- 55.8% vs 56.2% in 2Q 2025
- Operating Income Margin2 Q2026
- 31.1%
- Litigation Expense2026 Estimate
- below $1.6 million
Price after filing
Close on the filing date to close N calendar days later (from $72.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.